Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood

Haemophilia

Volumn 18, Issue 6, 2012, Pages 926-932

  Ogawa, S ^a   Szlam, F ^a   Dunn, A L ^b   Bolliger, D ^c,d   Ohnishi, T ^d   Hosokawa, K ^b   Tanaka, K A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pediatric Hematology/Oncology   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Fujimori Kogyo CO   (Japan)

Author keywords

Fibrin; Intrinsic tenases; Shear rate; Thrombin; Thrombus formation

Indexed keywords

APTAMER; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; COLLAGEN; DANAPAROID; FIBRIN; THROMBOPLASTIN; TRYPSIN INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; BLOOD SAMPLING; CAPILLARY; CONTROLLED STUDY; FEMALE; HEMOPHILIA B; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PERFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHEAR RATE; THROMBOCYTE; THROMBUS; VOLUNTEER; WILD TYPE;

ANIMALS; APTAMERS, NUCLEOTIDE; AUTOMATION; BLOOD CIRCULATION; BLOOD COAGULATION; BLOOD PLATELETS; FACTOR IXA; FACTOR VIII; FIBRIN; HUMANS; MICE; MICE, TRANSGENIC; MICROFLUIDIC ANALYTICAL TECHNIQUES; PROTEIN BINDING; SHEAR STRENGTH; THROMBOSIS;

EID: 84868210869     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02867.x     Document Type: Article

References (33)

1. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58: 741-53.
2. Hovig T, Dodds WJ, Rowsell HC, Mustard JF. The transformation of hemostatic platelet plugs in normal and Factor IX deficient dogs. Am J Pathol 1968; 53: 355-73.
3. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
4. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52-6.
5. Wartiovaara-Kautto U, Joutsi-Korhonen L, Ilveskero S, Armstrong E, Lassila R. Platelets significantly modify procoagulant activities in haemophilia A. Haemophilia 2011; 17: 743-51.
6. Brinkmann T, Kahnert H, Prohaska W, Nordfang O, Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994; 32: 313-7.
7. Franchini M, Montagnana M, Targher G et al.Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009; 35: 307-12.
8. Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Haemost 2010; 103: 1233-8.
9. Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D. Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. Blood 1992; 80: 988-94.
10. Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999; 94: 968-75.
11. Hosokawa K, Ohnishi T, Kondo T et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011; 9: 2029-37.
12. Ogawa S, Szlam F, Ohnishi T, Molinaro RJ, Hosokawa K, Tanaka KA. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions. Thromb Haemost 2011; 106: 1215-23.
13. Hosokawa K, Ohnishi T, Fukasawa M et al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 2012; 83: 154-61.
14. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
15. Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010; 16: 510-7.
16. Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007; 27: 722-7.
17. Szlam F, Luan D, Bolliger D et al. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin. Thromb Res 2010; 125: 432-7.
18. Chan MY, Cohen MG, Dyke CK et al.Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117: 2865-74.
19. Astrup T, Sjolin KE. Thromboplastic and fibrinolytic activity of human synovial membrane and fibrous capsular tissue. Proc Soc Exp Biol Med 1958; 97: 852-3.
20. Vanschoonbeek K, Feijge MA, Van Kampen RJ et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-84.
21. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
22. Dargaud Y, Beguin S, Lienhart A et al.Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
23. Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. Blood 1984; 63: 1004-14.
24. Hanson SR, Sakariassen KS. Blood flow and antithrombotic drug effects. Am Heart J 1998; 135: S132-45.
25. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-3.
26. Viuff D, Andersen S, Sorensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res 2010; 126: 144-9.
27. Ovanesov MV, Lopatina EG, Saenko EL et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb Haemost 2003; 89: 235-42.
28. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem 2005; 280: 42887-96.
29. Aird WC. Endothelial cell dynamics and complexity theory. Crit Care Med 2002; 30: S180-5.
30. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115: 3355-62.
31. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7: 1517-22.
32. Sharathkumar AA, Soucie JM, Trawinski B, Greist A, Shapiro AD. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia 2011; 17: 597-604.
33. MacKinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in patients with haemophilia. Haemophilia 2000; 6: 84-8.